Tag:
CR Bard
Latest Headlines
Latest Headlines
FDA: J&J, others must study safety of vaginal mesh
The FDA is ordering the makers of vaginal mesh implants to study the rates of organ damage and other complications following allegations that the devices have harmed women. The devices are used to...
Bard picks up Lutonix for $225M
Murray Hill, NJ-based C. R. Bard ( $BCR ) has bought venture-backed Lutonix for $225 million at closing, with an additional $100 million to be paid upon PMA approval of the latter's drug-coated
Lawmakers seek recall info from Medtronic, 4 others
Three U.S. senators have fired off investigative letters to 5 devicemakers seeking information on how the companies conduct post-market surveillance, as well as on how they manage recalls when a...
Bard to buy Medivance for $250M
Murray Hill, NJ-based C.R. Bard ( $BCR ) has reached an agreement to buy Medivance for roughly $250 million. Louisville, CO-based Medivance will become part of the Bard Medical division upon the
Panel mulls tougher rules for transvaginal meshes
Makers of vaginally implanted surgical meshes, including Johnson & Johnson ( $JNJ ), Endo Pharmaceuticals Holdings and C.R. Bard, could eventually be required to initiate studies on their products
C.R. Bard CFO to retire
C. R. Bard's Todd Schermerhorn, the company's senior vice president and CFO, will retire after a transition period that is expected to run through August 2012. The news comes almost two weeks after
C.R. Bard to pay $184M to end Davol suits
C.R. Bard will pay $184 million to settle a majority of the lawsuits filed against its Davol subsidiary involving the unit's Composix Kugel and other hernia repair implant products. More than 2,700
Davol's XenMatrix recalled on toxin concerns
The FDA has issued a Class I recall notice of a cloth-like surgical device made by C.R. Bard subsidiary Davol. XenMatrix Surgical Graft is used to treat hernia and abdominal wall repair, notes
Report: Bard to cut 200 jobs
C.R. Bard has finally revealed the number of jobs it will cut following an announcement in its Q4 earnings. The company, which manufactures vascular, urology, oncology and surgical specialty devices,
Earnings: Covidien sees devices sales up 11%, Bard reports positive results
Covidien and C.R. Bard were among the devicemakers to report earnings this week. Covidien reported that Q1 2011 net sales were $2.77 billion--up five percent from the $2.64 billion reported a year
